- Conducted by the Regenstrief Institute and Indiana University School of Medicine, the study involved over 21,000 average-risk patients across 186 sites in the U.S.
- Next-Generation Stool DNA Test: The research focused on a next-generation multi-target stool DNA colorectal cancer screening test, which was found to detect 94% of colorectal cancers.
- Superior Performance: This test demonstrated the best performance in detecting both colorectal cancer and advanced precancerous polyps compared to any other noninvasive colorectal cancer screening test.
- Study Results: Published in the New England Journal of Medicine, the study highlighted the test’s good balance of sensitivity (detecting disease) and specificity (low false positive results).
- Comparison with FIT Test: The next-generation stool DNA test outperformed the commonly used Fecal Immunochemical Test (FIT) in detecting cancers and was more sensitive in picking up advanced precancerous lesions. However, FIT had a lower overall false positive rate.
Next-generation stool DNA test found to have best detection rate of noninvasive colorectal cancer screening tools (Medical Xpress)
0